All In Biotech

NDA 021798 · Bristol Myers Squibb

Baraclude

Entecavir · Oral

Priority review

Last checked: Nov 20, 2026Latest source record: Aug 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Mar 29, 2005

Approved uses

9

Original approval plus efficacy supplements

Registered trials

277

40 Phase 3, 15 recruiting

FAERS reports

11,801

10,278 serious, 1,893 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SEVERE ACUTE EXACERBATIONS OF HEPATITIS B, PATIENTS CO-INFECTED WITH HIV AND HBV, and LACTIC ACIDOSIS AND HEPATOMEGALY Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti-hepatitis B therapy, including entecavir. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy. If appropriate, initiation of anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1) ]. Limited clinical experience suggests there is a potential for the development of resistance to HIV (human immunodeficiency virus) nucleoside reverse transcriptase inhibitors if BARACLUDE is used to treat chronic hepatitis B virus (HBV) infection in patients with HIV infection that is not being treated. Therapy with BARACLUDE is not recommended...

What it is approved for

From the label in effect Nov 6, 2019.

BARACLUDE ® (entecavir) is indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. BARACLUDE is a hepatitis B virus nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults and children at least 2 years of age with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. (1)

Mechanism: Entecavir is an antiviral drug against hepatitis B virus [see Microbiology (12.4) ]. Mechanism of Action Entecavir, a deoxyguanosine nucleoside analogue with activity against HBV reverse transcriptase (rt), is efficiently phosphorylated to the active triphosphate form, which has an intracellular half-life of 15 hours. By competing with the natural substrate deoxyguanosine triphosphate, entecavir triphosphate functionally inhibits all three activities of the HBV reverse transcriptase: (1) base priming, (2) reverse transcription of the negative strand from the pregenomic messenger RNA, and (3)...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 20, 2014 Supplement 19 · Efficacy · priority review LabelLetter
  • Oct 12, 2012 Supplement 16 · Efficacy LabelLetter
  • Oct 12, 2012 Supplement 14 · Efficacy LabelLetter
  • Oct 15, 2010 Supplement 11 · Efficacy Label
  • Jul 16, 2009 Supplement 8 · Efficacy LetterLabel
  • Jul 25, 2008 Supplement 6 · Efficacy LabelLetter
  • Mar 27, 2007 Supplement 2 · Efficacy LetterLabel
  • Feb 23, 2007 Supplement 1 · Efficacy LabelLetter
  • Mar 29, 2005 Original approval · Type 3 - New Dosage Form · priority review ReviewLabelLetter
1 products under this application
  • BARACLUDE · ENTECAVIR 0.05MG/ML · SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Entecavir" as an intervention, any sponsor and status, largest first.

All 277 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death554
  • off label use553
  • drug ineffective451
  • drug resistance407
  • diarrhoea389
  • pyrexia372
  • fatigue369
  • hepatitis b332
  • nausea328
  • pneumonia309
  • platelet count decreased302
  • anaemia238

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
200515
200664
2007193
2008160
2009234
2010308
2011317
2012433
2013378
2014654
2015652
2016823
2017761
2018787
2019858
2020740
2021758
2022793
2023783
2024796
2025755
2026537

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Baraclude (Entecavir)

2024 spending

$2.7M

Beneficiaries

268

1,512 claims

Per beneficiary

$9,916

$31.28 per unit

View as table
YearSpending
2020$3,773,750
2021$3,454,380
2022$3,079,598
2023$2,808,858
2024$2,657,561

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 435 on PubMed

Sponsor: Bristol Myers Squibb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.